Acutus Medical, Inc. (AFIB) Stock Price & Analysis
Acutus Medical, Inc. (AFIB) — price $0.0001 (0.00%), as of the Nov 19, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Acutus Medical, Inc. · AFIB
Acutus Medical, Inc. is an arrhythmia management company specializing in catheter-based ablation tools for treating various arrhythmias.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $0.0001 |
| Change on the day | 0.00% |
| Shares traded on the day | 10.0K |
Price & events
Other perspectives
Council score for Acutus Medical (AFIB): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Acutus Medical (AFIB), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Acutus Medical, Inc. (AFIB) is the company analyzed here. It employs 85 people. In Q4 FY2024 it reported revenue of $7M and net income of -$1M.
What do the latest results show for Acutus Medical (AFIB)?
Short answer · as of
The most recent reported quarter, Q4 FY2024, carried revenue of $7M. Against analyst estimates the company has EPS beat 6 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2024 | $7M | -$1M | -$0.05 (diluted) |
| Q3 FY2024 | $5M | -$6M | -$0.19 (diluted) |
| Q2 FY2024 | $4M | -$914,000 | -$0.03 (diluted) |
| Q1 FY2024 | $4M | -$2M | -$0.05 (diluted) |
What are the financial strengths and risks for Acutus Medical (AFIB)?
Short answer · as of
The distress and quality screens read Altman Z -28.39 · Piotroski F 3. Trailing ratios: ROE 153.1% · ROA -33.3% · current ratio 2.06.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -28.39 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at Acutus Medical (AFIB)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $98.80M · EPS -1.35 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- The newest quarter held here (Q4 FY2024) was filed Mar 24, 2025 — 14 months ago.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $98.80M
- EPS estimate
- $-1.35
Measured against a quoted price of $0.0001 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 5
- Purchases
- 0
- Sales
- 0
- Other transactions
- 12
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held AFIB in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported AFIB in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Investor Questions: AFIB Stock
These answers are editorial: 1 of these 1 answer is drawn from the AFIB research dossier (written Jun 14, 2026 by gpt-4o-mini). Figures in this section are not part of the source register.
What does Acutus Medical, Inc. do?
Acutus Medical, Inc. specializes in the design and manufacture of advanced catheter-based tools for the treatment of cardiac arrhythmias. Their product portfolio includes diagnostic and mapping catheters, ablation catheters, and supporting software solutions, aimed at improving patient outcomes in electrophysiology.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 9 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com